PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022

In vaccine dominated space for the treatment of Meningococcal disease, Meningococcal vaccines market foresees a spectacular growth during 2011-2022. MenB vaccine market is expected to grow at a rapid pace during the 10 years period. With adolescents being the target, Pfizer is anticipated to be in rapid uptake, given the ACIP’s current immunization recommendations (CDC, 2013b). As the MenACWY share is predicted to remain stagnant, MenB appears poised to take off in the US, reveals the report.

With the launch of Serotype B vaccine, a critical unmet need in the treatment of Meningococcal disease is expected to be shared with tetravalent conjugate vaccines such as Sanofi’s Menactra and Novartis’ Menveo. As the acute infection’s rapid onset and severity of symptoms’ diagnosis is highly difficult, vaccines play a key role in fighting of the disease caused by the gram-negative bacterium Neisseria meningitidis.

Spanning over 119 pages, 34 tables and 3 figures, “PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022” report addresses key factors such as analysis of the impact of key events, understanding and capitalizing by identifying products that are most likely to ensure a robust return, opportunities and improvements, understanding of the changing competitive landscape, planning your M&A and partnership strategies and sales forecast for the top drugs in the US from 2012-2022.

Browse more Pharma and Healthcare Market Research Reports